EMA's September 2026 NAM data pilot lets sponsors share organ-chip and computational data directly with regulators, reshaping ...

Veeva Falcon Safety's E2B(R3) interoperability across all input channels signals the end of dual-entry SAE workflows—here's ...

Girl with Griscelli Syndrome Type II receives first haploidentical transplant at Miami hospital, offering new hope for ...

Elevar presents age-stratified camrelizumab-rivoceranib data from Phase 3 CARES-310 after two FDA rejections, signaling ...

PMV Pharma's rezatapopt achieves 44% response rate in TP53 Y220C ovarian cancer patients, positioning the drug for potential ...

Scale AI's CliniCARE-Bench found 34.7% error rates and right-answer-wrong-process failures. The clinical trials field has no ...

A 38,753-patient cross-trial synthesis in Nature Medicine maps short-term safety of HF combination therapies—signaling how ...

Aprea's APR-1051 early signals are forcing a rapid site expansion—here's what the enrollment acceleration actually costs at ...

Orexo AB settled a 6-year DOJ opioid-marketing investigation for $4M, but the press release names no conduct, no victims, no ...

SRD-002 gene therapy shows sustained HFpEF improvement at 12 months with 80% PCWP normalization from a single intracoronary ...

Mechanical thrombectomy for STEMI with large thrombus burden reduced infarct size by 26% in the NATURE trial, meeting its ...

FDA's July 2026 approval of at-home subcutaneous lecanemab initiation eliminates the 18-month IV requirement, reshaping CNS ...